Implementation and benchmarking of a novel analytical framework to clinically evaluate tumor-specific fluorescent tracers

Marjory Koller, Si-Qi Qiu, Matthijs D Linssen, Liesbeth Jansen, Wendy Kelder, Jakob de Vries, Inge Kruithof, Guo-Jun Zhang, Dominic J Robinson, Wouter B Nagengast, Annelies Jorritsma-Smit, Bert van der Vegt, Gooitzen M van Dam

Research output: Contribution to journalArticleAcademicpeer-review

31 Citations (Scopus)
301 Downloads (Pure)

Abstract

During the last decade, the emerging field of molecular fluorescence imaging has led to the development of tumor-specific fluorescent tracers and an increase in early-phase clinical trials without having consensus on a standard methodology for evaluating an optical tracer. By combining multiple complementary state-of-the-art clinical optical imaging techniques, we propose a novel analytical framework for the clinical translation and evaluation of tumor-targeted fluorescent tracers for molecular fluorescence imaging which can be used for a range of tumor types and with different optical tracers. Here we report the implementation of this analytical framework and demonstrate the tumor-specific targeting of escalating doses of the near-infrared fluorescent tracer bevacizumab-800CW on a macroscopic and microscopic level. We subsequently demonstrate an 88% increase in the intraoperative detection rate of tumor-involved margins in primary breast cancer patients, indicating the clinical feasibility and support of future studies to evaluate the definitive clinical impact of fluorescence-guided surgery.

Original languageEnglish
Article number3739
Number of pages11
JournalNature Communications
Volume9
Issue number1
DOIs
Publication statusPublished - 18-Sep-2018

Keywords

  • BREAST-CONSERVING SURGERY
  • STAGE-I
  • CANCER
  • MARGINS
  • IRRADIATION
  • THERAPY
  • SAFETY
  • 1ST

Cite this